NCT05157776 trial: what clinicians have said so far
A Phase III Trial of Neoadjuvant Sintilimab and Chemotherapy for NSCLC Harboring No Driver Mutations
- NCT05157776 ↗
- Unknown
- Tongji University
- Focused size, estimated: 1–150 verified statements once built
We haven't built an HCP commentary report on NCT05157776 (sintilimab in resectable locally advanced NSCLC harboring no driver mutations) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on NCT05157776 so far
Podcasts, YouTube videos and posts on X and Bluesky we have indexed that name the trial. LinkedIn posts are read for reports and the Enterprise MCP, not yet for this index. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Indexed so far | |
|---|---|
| 3 posts on X, typically up to 13 once built |
The trial
ClinicalTrials.gov- Official title
- Neoadjuvant Sintilimab and Platinum-based Chemotherapy for Resectable Locally Advanced NSCLC Harboring no Driver Mutations: A Prospective, Randomized, Multicenter Phase III Trial
- Phase
- Phase 3
- Status
- Unknown
- Conditions
- NSCLC, Stage IIIA; EGF-R Negative Non-Small Cell Lung Cancer; ALK Negative NSCLC
- Interventions
- PD-1 and chemotherapy
- Arms
- Control group · Active comparator
- Experimental group · Experimental
- Enrollment
- 72 (estimated)
- Primary outcomes
- Pathologically complete response (pCR) rate
- Sponsor
- Tongji University
- Start
- Oct 28, 2021
- Primary completion
- Oct 31, 2024 (estimated)
- Results posted
- No
- Registry record
- NCT05157776 · updated May 9, 2023
Publications
linked from the registry- Lin D, Wu L, Wang P, Li X, Wang X, Cai Y, Xiong K, Chen X, Yang F, Huang W, Wang X, Fan J. Dynamic circulating tumor DNA indicates pathological benefits of additional neoadjuvant chemoimmunotherapy courses for locally advanced non-small-cell lung cancer patients. Front Oncol. 2025 Jul 24;15:1563315. doi: 10.3389/fonc.2025.1563315. eCollection 2025. PubMed 40777124